OxyContin wins 'abuse-deterrent' label, but FDA bans older generic forms
This article was originally published in Scrip
Three years after the FDA OK'd Purdue Pharma's reformulated version of its controlled-release oxycodone drug, OxyContin, the company won the coveted "abuse-deterrent" language in the medicine’s labeling.
You may also be interested in...
Potential sales impact of even broadest possible label for oral, intranasal and intravenous abuse remains a question mark given that abuse-deterrent products remain only a small percentage of market.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.